Pharmaceuticals

When you hear about the likes of “Apple”, “Amazon”, “Facebook”, “Google” and Microsoft”, healthcare is not typically the first thing that springs to mind. However, in recent years these tech giants have been emerging in the healthcare sector. What triggered this diversity in their market strategy? How might this affect...

The first AIDS-related deaths began to surface almost 40 years ago in 1981. At that time, we had no effective medication and AIDS was a certain death sentence. At its peak, the AIDS crisis was killing 2 million people each year – people from all corners of society and across the...

On Wednesday 5th June, Gill Jennings & Every hosted an event to investigate how Artificial Intelligence (AI) and Machine Learning (ML) are transforming digital healthcare and pharmaceuticals.  We brought together an expert panel to help us find out more about the different ways AI is being implemented and their advantages...

In Europe, Supplementary Protection Certificates (SPCs) compensate patentees for the inevitable delay in obtaining Marketing Authorisation by extending exclusivity for a marketable pharmaceutical or plant protection product by up to five years (five-and-a-half years for paediatric medicines) following the expiry of the related patent protection. Earlier this year, the EU...

Every so often, the European Patent Office issues a decision on a case which has important consequences for other patent applicants. The recent decision T1085/13 (discussed in greater detail here) has implications for how purity claims are assessed at the EPO and may be seen as patentee-friendly, particularly for the...